APA

Genovese M. C., Van den Bosch F., Roberson S. A., Bojin S., Biagini I. M., Ryan P. & Sloan-Lancaster J. (20100504). LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. : Arthritis and rheumatism.

Chicago

Genovese M C, Van den Bosch F, Roberson S A, Bojin S, Biagini I M, Ryan Peter and Sloan-Lancaster J. 20100504. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. : Arthritis and rheumatism.

Harvard

Genovese M. C., Van den Bosch F., Roberson S. A., Bojin S., Biagini I. M., Ryan P. and Sloan-Lancaster J. (20100504). LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. : Arthritis and rheumatism.

MLA

Genovese M C, Van den Bosch F, Roberson S A, Bojin S, Biagini I M, Ryan Peter and Sloan-Lancaster J. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. : Arthritis and rheumatism. 20100504.